Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (otvara novi prozor)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Izvor‎: Ann Intern Med 2008;148(12):939-55.

Indeks‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (otvara novi prozor)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (otvara novi prozor)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Izvor‎: Am J Hematol 2000;64(1):26-31.

Indeks‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (otvara novi prozor)

Hydroxyurea for the treatment of sickle cell anemia. (otvara novi prozor)

Platt OS.

Izvor‎: N Engl J Med 2008;358(13):1362-9.

Indeks‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (otvara novi prozor)

Clinical effectiveness of decitabine in severe sickle cell disease. (otvara novi prozor)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Izvor‎: Br J Haematol 2008;141(1):126-9.

Indeks‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (otvara novi prozor)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (otvara novi prozor)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Izvor‎: Blood 2010;115(12):2354-63.

Indeks‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (otvara novi prozor)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (otvara novi prozor)

Hirst C, Owusu-Ofori S.

Izvor‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indeks‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (otvara novi prozor)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (otvara novi prozor)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Izvor‎: Lancet Haematol 2021;8(5):e323-33.

Indeks‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (otvara novi prozor)

Sickle cell disease. (otvara novi prozor)

Meremikwu MM, Okomo U.

Izvor‎: BMJ Clin Evid 2011;02:2402.

Indeks‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (otvara novi prozor)

A phase 3 trial of l-glutamine in sickle cell disease. (otvara novi prozor)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Izvor‎: N Engl J Med 2018;379(3):226-35.

Indeks‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (otvara novi prozor)

Malaria chemoprophylaxis in sickle cell disease. (otvara novi prozor)

Oniyangi O, Omari AA.

Izvor‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indeks‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (otvara novi prozor)